Alan Green
Allergy/ Immunology · Glendale, CANPI 1609907732
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AstraZeneca at 31.5% of the total. Reporting peaked in 2019 at $160 and has fallen 90.5% since, to $15 in 2025.
Across 29 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$157
- GSK$144
- Sanofi$39
- Amgen$27
- Boehringer Ingelheim$23
- Teva Pharmaceuticals USA, Inc.$20
- plus $88 from 6 others
What the payments were for
- Food & beverage$498100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $157 |
| GSK | 7 | $144 |
| Sanofi | 2 | $39 |
| Amgen | 1 | $27 |
| Boehringer Ingelheim | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Merck | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Optinose US, Inc. | 1 | $17 |
| Boston Scientific | 1 | $13 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
| Circassia Inc. | 1 | $11 |
How this compares
Too few allergy/ immunology providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atrovent HfaIpratropium Bromide | 32 | $23,319 |
| Advair HfaFluticasone Propion/Salmeterol | 43 | $14,237 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $11,568 |
| Spiriva HandihalerTiotropium Bromide | 21 | $10,791 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $8,249 |
| Fluticasone Propionate HfaFluticasone Propionate | 29 | $8,180 |
| Qvar RedihalerBeclomethasone Dipropionate | 26 | $8,176 |
| Spiriva RespimatTiotropium Bromide | 14 | $7,107 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $6,866 |
| Serevent DiskusSalmeterol Xinafoate | 12 | $4,579 |
| Pulmicort FlexhalerBudesonide | 12 | $2,861 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $2,012 |
| Zafirlukast | 11 | $1,388 |
| Montelukast Sodium | 135 | $1,385 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $387 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Incruse Ellipta | $144 | $19,81742 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $157 | $9,72733 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $20 | $8,17626 claims |
| Boehringer IngelheimSpiriva Respimat | $23 | $7,10714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in Californiaon file to place this against a meaningful peer group, so we don't.
Other allergy/ immunology in Glendale
- Gregory BenschStockton$2M
- George BenschStockton$78K
- Schuman TamSan Francisco$23K
- Cristina PorchcurrenCamarillo$19K
- Steven PragerSalinas$9K
- William CreightonBrawley$8K
- Janet Kershaw-MclennanAtascadero$8K
- Reyneiro CastroPasadena$7K
- Shouling ZhangDowney$3K
- Michael ReidSan Francisco$937
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.